DK1026950T3 - Behandling af skizofreni med ampakiner og neuroleptika - Google Patents

Behandling af skizofreni med ampakiner og neuroleptika

Info

Publication number
DK1026950T3
DK1026950T3 DK98957382T DK98957382T DK1026950T3 DK 1026950 T3 DK1026950 T3 DK 1026950T3 DK 98957382 T DK98957382 T DK 98957382T DK 98957382 T DK98957382 T DK 98957382T DK 1026950 T3 DK1026950 T3 DK 1026950T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
treatment
ampakines
neuroleptics
relates
Prior art date
Application number
DK98957382T
Other languages
English (en)
Inventor
Steven A Johnson
Gary A Rogers
Gary S Lynch
Original Assignee
Univ California
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1026950(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Cortex Pharma Inc filed Critical Univ California
Application granted granted Critical
Publication of DK1026950T3 publication Critical patent/DK1026950T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK98957382T 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika DK1026950T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
DK1026950T3 true DK1026950T3 (da) 2006-06-26

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957382T DK1026950T3 (da) 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika

Country Status (15)

Country Link
US (1) US6166008A (da)
EP (1) EP1026950B1 (da)
JP (1) JP2001520978A (da)
CN (1) CN1281335A (da)
AT (1) ATE317226T1 (da)
AU (1) AU745641B2 (da)
BR (1) BR9814106A (da)
CA (1) CA2306817A1 (da)
CY (1) CY1105557T1 (da)
DE (1) DE69833451T2 (da)
DK (1) DK1026950T3 (da)
ES (1) ES2258825T3 (da)
HK (1) HK1030338A1 (da)
PT (1) PT1026950E (da)
WO (1) WO1999021422A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333299T2 (de) 1992-07-24 2004-09-09 The Regents Of The University Of California, Oakland Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Response erhöhen
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
CA2456942A1 (en) * 2001-08-10 2003-02-20 The Rockefeller University Compositions and methods for modulation of darpp-32 phosphorylation
NZ540468A (en) * 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7282519B2 (en) 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2006091716A2 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
MX2007012659A (es) 2005-04-13 2008-01-11 Astex Therapeutics Ltd Derivados de hidroxi-benzamida y su uso como inhibidores de hsp90.
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
MX2010001631A (es) 2007-08-10 2010-03-15 Cortex Pharma Inc Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas.
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
KR20110115139A (ko) * 2009-02-02 2011-10-20 코텍스 파마슈티칼스, 인크. 글루타메이트성 시냅틱 반응을 향상시키기 위한 비시클릭 아미드 유도체
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2801377B1 (en) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
AU2013271609A1 (en) 2012-06-05 2014-12-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using NCAM peptide mimetics
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
WO1999021422A1 (en) 1999-05-06
ATE317226T1 (de) 2006-02-15
CY1105557T1 (el) 2010-07-28
EP1026950A1 (en) 2000-08-16
AU745641B2 (en) 2002-03-28
DE69833451T2 (de) 2006-09-28
ES2258825T3 (es) 2006-09-01
HK1030338A1 (en) 2001-05-04
EP1026950A4 (en) 2004-07-07
PT1026950E (pt) 2006-06-30
AU1365899A (en) 1999-05-17
US6166008A (en) 2000-12-26
CA2306817A1 (en) 1999-05-06
DE69833451D1 (de) 2006-04-20
EP1026950B1 (en) 2006-02-08
CN1281335A (zh) 2001-01-24
JP2001520978A (ja) 2001-11-06
BR9814106A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
DK1026950T3 (da) Behandling af skizofreni med ampakiner og neuroleptika
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
DE69429524T2 (de) Aminocyclohexylester und ihre anwendung
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
DE69813898D1 (de) Substituierte porphyrinen
SE9900100D0 (sv) New compounds
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
DE122010000038I1 (de) Pyrimidinamine als angiogenesemodulatoren
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
TR199902334T2 (xx) Psikotik bozukluklar�n tedavisi veya profilaksisi i�in mirtazapin ve antipsikotik ajanlar�n yeni terap�tik kombinasyonlar�.
DE60025639D1 (de) Substituierte diazepan
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TR200200278T2 (tr) Kalsilitik bileşimler
TW200503717A (en) Substituted 1,4-pyrazine derivatives
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
TR200000916T2 (tr) İkameli piperidin türevleri.